Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001)

Susan M. Blaney, James Boyett, Henry Friedman, Amar Gajjar, Russ Geyer, Marc Horowtiz, Daniel Hunt, Mark Kieran, Larry Kun, Roger Packer, Peter Phillips, Ian F. Pollack, Michael Prados, Richard Heideman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: A phase I trial of intrathecal (IT) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence and severity of other toxicities when administered in association with concomitant multiagent systemic chemotherapy to children younger than 3 years with newly diagnosed embryonal tumors. Patients and Methods: Twenty-five assessable patients received IT mafosfamide at one of six dose levels ranging from 5 mg to 17 mg. Patients were premedicated with dexamethasone (0.15 mg/kg) and morphine (0.1 mg/kg) before receiving IT mafosfamide. Serial samples of CSF for pharmacokinetic studies were obtained in a subset of patients with Ommaya reservoirs. Results: Irritability, presumably secondary to pain or headache during mafosfamide administration, was dose limiting in two of three patients at the 17-mg dose level. The maximum-tolerated dose of IT mafosfamide following premedication with dexamethasone and morphine was 14 mg. Conclusion: The maximum tolerated dose and recommended phase II dose of IT mafosfamide in patients younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg. A trial to assess the efficacy of regional therapy with IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years with primary intracranial embryonal tumors is now in progress.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number3
DOIs
StatePublished - Dec 1 2005

Fingerprint

Clinical Trials, Phase I
Brain Neoplasms
Pediatrics
Neoplasms
Maximum Tolerated Dose
Morphine
Dexamethasone
Drug Therapy
Premedication
mafosfamide
Headache
Pharmacokinetics
Pain
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors : A Pediatric Brain Tumor Consortium Study (PBTC-001). / Blaney, Susan M.; Boyett, James; Friedman, Henry; Gajjar, Amar; Geyer, Russ; Horowtiz, Marc; Hunt, Daniel; Kieran, Mark; Kun, Larry; Packer, Roger; Phillips, Peter; Pollack, Ian F.; Prados, Michael; Heideman, Richard.

In: Journal of Clinical Oncology, Vol. 23, No. 3, 01.12.2005, p. 525-531.

Research output: Contribution to journalArticle

Blaney, SM, Boyett, J, Friedman, H, Gajjar, A, Geyer, R, Horowtiz, M, Hunt, D, Kieran, M, Kun, L, Packer, R, Phillips, P, Pollack, IF, Prados, M & Heideman, R 2005, 'Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001)', Journal of Clinical Oncology, vol. 23, no. 3, pp. 525-531. https://doi.org/10.1200/JCO.2005.06.544
Blaney, Susan M. ; Boyett, James ; Friedman, Henry ; Gajjar, Amar ; Geyer, Russ ; Horowtiz, Marc ; Hunt, Daniel ; Kieran, Mark ; Kun, Larry ; Packer, Roger ; Phillips, Peter ; Pollack, Ian F. ; Prados, Michael ; Heideman, Richard. / Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors : A Pediatric Brain Tumor Consortium Study (PBTC-001). In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 3. pp. 525-531.
@article{f0a54ffff6eb42609c8763abc8bd71b0,
title = "Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001)",
abstract = "Purpose: A phase I trial of intrathecal (IT) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence and severity of other toxicities when administered in association with concomitant multiagent systemic chemotherapy to children younger than 3 years with newly diagnosed embryonal tumors. Patients and Methods: Twenty-five assessable patients received IT mafosfamide at one of six dose levels ranging from 5 mg to 17 mg. Patients were premedicated with dexamethasone (0.15 mg/kg) and morphine (0.1 mg/kg) before receiving IT mafosfamide. Serial samples of CSF for pharmacokinetic studies were obtained in a subset of patients with Ommaya reservoirs. Results: Irritability, presumably secondary to pain or headache during mafosfamide administration, was dose limiting in two of three patients at the 17-mg dose level. The maximum-tolerated dose of IT mafosfamide following premedication with dexamethasone and morphine was 14 mg. Conclusion: The maximum tolerated dose and recommended phase II dose of IT mafosfamide in patients younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg. A trial to assess the efficacy of regional therapy with IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years with primary intracranial embryonal tumors is now in progress.",
author = "Blaney, {Susan M.} and James Boyett and Henry Friedman and Amar Gajjar and Russ Geyer and Marc Horowtiz and Daniel Hunt and Mark Kieran and Larry Kun and Roger Packer and Peter Phillips and Pollack, {Ian F.} and Michael Prados and Richard Heideman",
year = "2005",
month = "12",
day = "1",
doi = "10.1200/JCO.2005.06.544",
language = "English (US)",
volume = "23",
pages = "525--531",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors

T2 - A Pediatric Brain Tumor Consortium Study (PBTC-001)

AU - Blaney, Susan M.

AU - Boyett, James

AU - Friedman, Henry

AU - Gajjar, Amar

AU - Geyer, Russ

AU - Horowtiz, Marc

AU - Hunt, Daniel

AU - Kieran, Mark

AU - Kun, Larry

AU - Packer, Roger

AU - Phillips, Peter

AU - Pollack, Ian F.

AU - Prados, Michael

AU - Heideman, Richard

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: A phase I trial of intrathecal (IT) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence and severity of other toxicities when administered in association with concomitant multiagent systemic chemotherapy to children younger than 3 years with newly diagnosed embryonal tumors. Patients and Methods: Twenty-five assessable patients received IT mafosfamide at one of six dose levels ranging from 5 mg to 17 mg. Patients were premedicated with dexamethasone (0.15 mg/kg) and morphine (0.1 mg/kg) before receiving IT mafosfamide. Serial samples of CSF for pharmacokinetic studies were obtained in a subset of patients with Ommaya reservoirs. Results: Irritability, presumably secondary to pain or headache during mafosfamide administration, was dose limiting in two of three patients at the 17-mg dose level. The maximum-tolerated dose of IT mafosfamide following premedication with dexamethasone and morphine was 14 mg. Conclusion: The maximum tolerated dose and recommended phase II dose of IT mafosfamide in patients younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg. A trial to assess the efficacy of regional therapy with IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years with primary intracranial embryonal tumors is now in progress.

AB - Purpose: A phase I trial of intrathecal (IT) mafosfamide was performed to determine the optimal dose, dose-limiting toxicities, and incidence and severity of other toxicities when administered in association with concomitant multiagent systemic chemotherapy to children younger than 3 years with newly diagnosed embryonal tumors. Patients and Methods: Twenty-five assessable patients received IT mafosfamide at one of six dose levels ranging from 5 mg to 17 mg. Patients were premedicated with dexamethasone (0.15 mg/kg) and morphine (0.1 mg/kg) before receiving IT mafosfamide. Serial samples of CSF for pharmacokinetic studies were obtained in a subset of patients with Ommaya reservoirs. Results: Irritability, presumably secondary to pain or headache during mafosfamide administration, was dose limiting in two of three patients at the 17-mg dose level. The maximum-tolerated dose of IT mafosfamide following premedication with dexamethasone and morphine was 14 mg. Conclusion: The maximum tolerated dose and recommended phase II dose of IT mafosfamide in patients younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg. A trial to assess the efficacy of regional therapy with IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years with primary intracranial embryonal tumors is now in progress.

UR - http://www.scopus.com/inward/record.url?scp=20044369691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044369691&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.06.544

DO - 10.1200/JCO.2005.06.544

M3 - Article

C2 - 15659498

AN - SCOPUS:20044369691

VL - 23

SP - 525

EP - 531

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -